Descrizione del progetto
Un dispositivo innovativo per la separazione del siero
I rifiuti a rischio biologico vengono inceneriti ed è così che viene abitualmente smaltito circa il 95 % del sangue prelevato tramite venipuntura, non utilizzato per le rilevazioni diagnostiche. Il progetto SCAUT, finanziato dall’UE, sta sviluppando un dispositivo che abbina la separazione del siero al prelievo del sangue, utilizzando solo poche gocce di sangue per mezzo di un pungidito. Questo dispositivo di facile utilizzo, collegato a centri diagnostici centralizzati, sostituirà le provette per il prelievo di sangue e ridurrà la necessità di personale specializzato, stoccaggio a freddo e centrifuga. Il progetto fornirà una versione del dispositivo pronta per il mercato, ne dimostrerà le prestazioni cliniche e svilupperà una piattaforma automatizzata per il trattamento del siero compatibile con le attrezzature diagnostiche di laboratorio esistenti.
Obiettivo
95% of blood collected via venipuncture is not used for diagnostic measurements, and needs to be disposed as biohazardous waste by incineration, which is incredibly wasteful and taxing on our environment. In Europe, there is an urgent need for innovative approaches that engage vulnerable groups and increase access to infectious disease testing by breaking-down social and logistic barriers to healthcare. The decentralization of healthcare have created a need for a simple, safe, standardized and painless collection of serum specimens. The Ser-Col® is a novel serum separation device that simplifies and combines both blood collection and serum separation. With a few drops of blood from a finger stick, serum can be collected which is stable for several months prior to analysis of clinically relevant serum parameters, and thereby reducing biohazardous waste production by 50%. Ser-Col simplifies and reduces the cost of serum sampling by replacing the blood tube, trained personnel, cold storage, and centrifuge with a reliable and easy to use device that links target population to centralized diagnostics laboratories, ultimately leading to the long-term reduction of the burden of infectious diseases. The SCAUT consortium will scale up manufacturing to deliver a market ready version of the Ser-Col and validate its clinical performance against existing standards. To ensure market uptake the consortium will develop an automated serum processing platform for optimal compatibility with exciting laboratory diagnostic equipment and facilitate adoption of Ser-Col by healthcare professionals. This will accelerate commercialization, attract investors and to establish industry partnerships required to realize the full potential of the technology. The SCAUT project seeks to obtain €3 million to finalize the analytical and clinical validation and go-to-market of the Ser-Col® device. The estimated cumulative profit is €463.813 in 2023 increasing towards €18 million in 2027.
Campo scientifico
- medical and health scienceshealth sciencesinfectious diseases
- social sciencessociologysocial issuessocial inequalities
- engineering and technologyenvironmental engineeringwaste managementwaste treatment processes
- engineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
IA - Innovation actionCoordinatore
1906 BE Limmen
Paesi Bassi
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.